• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, June 29

Aurobindo Pharma Ltd has announced that it has received tentative approval from the US Food and Drug Administration (USFDA) for Stavudine capsules in 15 mg and 20 mg dosages.

In a press release here on Thursday, the company said this is in addition to the 30 mg and 40 mg capsules already approved in July last year. According to the company, the USFDA tentatively approved the total application covering 15, 20, 30 and 40 mg. The company said that Stavudine would now be available for consideration for purchase under the US President's Emergency Programme for AIDS Relief. The company manufactures both active pharmaceutical ingredients and formulation for this generic.

More Stories on : Standards & Benchmarks | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Qualcomm, Reliance meet ends in stalemate

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line